# A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02)

> **NCT02943564** · PHASE3 · COMPLETED · sponsor: **Naurex, Inc, an affiliate of Allergan plc** · enrollment: 658 (actual)

## Conditions studied

- Depressive Disorder, Major

## Interventions

- **DRUG:** Rapastinel
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02943564
- **Lead sponsor:** Naurex, Inc, an affiliate of Allergan plc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-01
- **Primary completion:** 2018-12-12
- **Final completion:** 2018-12-18
- **Target enrollment:** 658 (ACTUAL)
- **Last updated:** 2019-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02943564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02943564, "A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02943564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*